MOLOGIC INC.

Mologic Inc. specializes in the design, development, and deployment of rapid diagnostic instruments for infectious disease detection, with demonstrated expertise in analytical laboratory instrumentation for point-of-care and home-use applications. The company’s technical capabilities center on the engineering of antigen-based diagnostic platforms, including assay development, microfluidic system integration, and portable device manufacturing compliant with clinical and regulatory standards. Their work on the SARS-CoV-2 antigen home test under the RADx program reflects proficiency in translating molecular diagnostics into user-friendly, FDA-authorized devices optimized for non-laboratory environments, emphasizing speed, accuracy, and scalability in public health emergencies. Mologic Inc. has delivered critical diagnostic solutions to the Department of Health and Human Services, primarily supporting emergency response initiatives under the Rapid Acceleration of Diagnostics program. Their engagement with HHS underscores a focused relationship in advancing public health infrastructure through innovative point-of-care diagnostics, particularly during national health crises. The contractor’s contributions align with HHS’s mission to expand accessible, reliable testing capacity outside traditional clinical settings. The company’s primary industry focus is in analytical laboratory instrument manufacturing, specifically developing compact, high-sensitivity diagnostic tools for pathogen detection. This vertical specialization positions Mologic within the biomedical device sector, serving federal health security and emergency preparedness markets. Their work bridges the gap between laboratory-grade analytics and field-deployable technology, targeting applications where rapid, accurate results are essential for outbreak containment. Mologic Inc. is a small business structured as a 2L entity, headquartered in Hudson, Massachusetts. While currently holding no formal government certifications, its technical execution in regulated diagnostic device development demonstrates alignment with FDA and CLIA standards. The company maintains a focused presence in the federal biomedical innovation space, leveraging localized engineering talent to support national health security objectives.